nach oben

Community Mental Health Journal

Erschienen in:

10.11.2017 | Original Paper

Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy

verfasst von: Robert O. Cotes, David R. Goldsmith, Sarah L. Kopelovich, Cathy A. Lally, Benjamin G. Druss

Erschienen in: Community Mental Health Journal | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Antipsychotic polypharmacy (APP) is a common strategy despite guidelines advising against this practice. This article seeks to quantify the prevalence and correlates of APP using Medicaid Analytic eXtract files from 2003 to 2004. Nineteen percent of Medicaid recipients who received an antipsychotic were treated with APP. Individuals who received APP were more likely to be white, male, disabled, between the ages of 18–29, diagnosed with a psychotic disorder, and diagnosed with a higher number of psychiatric conditions. Geographic variation in APP rates was also observed. Quality improvement initiatives may help reduce APP for medically vulnerable patients.

Aggarwal, N. K., Rosenheck, R. A., Woods, S. W., & Sernyak, M. J. (2012). Race and long-acting antipsychotic prescription at a community mental health center: A retrospective chart review. The Journal of Clinical Psychiatry, 73(4), 513–517.CrossRefPubMed

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596–601.CrossRef

Anil Yagcioglu, A. E., Kivircik Akdede, B. B., Turgut, T. I., Tumuklu, M., Yazici, M. K., Alptekin, K.,.. ., & Meltzer, H. Y. (2005). A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. The Journal of Clinical Psychiatry, 66(1), 63–72.CrossRefPubMed

Baandrup, L., Allerup, P., Lublin, H., Nordentoft, M., Peacock, L., & Glenthoj, B. (2010). Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients. Acta Psychiatrica Scandinavica, 122(5), 367–374.CrossRefPubMed

Becker, E. R., Constantine, R. J., McPherson, M. A., & Jones, M. E. (2013). Antipsychotic polypharmacy prescribing patterns and costs in the Florida adult and child Medicaid populations. Journal of Health Care Finance, 40(1), 40–67.PubMed

Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A.,..., & Keller, W. (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin, 36(19955390), 71–93.CrossRefPubMed

Carnahan, R. M., Lund, B. C., Perry, P. J., & Chrischilles, E. A. (2006). Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatrica Scandinavica, 113(2), 135–141.CrossRefPubMed

Centers for Medicare & Medicaid Services. (2017). Medicaid Managed Care Trends and Snapshots 2000–2013. Retrieved January 3, 2017, from https://www.medicaid.gov/medicaid-chip-program-information/by-topics/data-and-systems/medicaid-managed-care/downloads/2013-medicaid-managed-care-trends-and-snapshots-2000-2013.pdf.

Centorrino, F., Goren, J. L., Hennen, J., Salvatore, P., Kelleher, J. P., & Baldessarini, R. J. (2004). Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. The American Journal of Psychiatry, 161(15056517), 700–706.CrossRefPubMed

Chakos, M. H., Glick, I. D., Miller, A. L., Hamner, M. B., Miller, D. D., Patel, J. K.,..., & Rosenheck, R. A. (2006). Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services, 57(8), 1094–1101.CrossRefPubMed

Citrome, L., Jaffe, A., Levine, J., Allingham, B., & Robinson, J. (2004). Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatric Services, 55(9), 1006–1013.CrossRefPubMed

Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002). Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin, 28(12047024), 75–84.CrossRefPubMed

Constantine, R. J., Andel, R., & Tandon, R. (2010). Trends in adult antipsychotic polypharmacy: Progress and challenges in Florida’s Medicaid program. Community Mental Health Journal, 46(6), 523–530.CrossRefPubMed

Correll, C. U. (2007). Acute and long-term adverse effects of antipsychotics. CNS Spectrums, 12(18389927), 10–14.CrossRefPubMed

Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009). Antipsychotic combinations vs. monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Bulletin, 35(2), 443–457.CrossRefPubMed

Correll, C. U., Shaikh, L., Gallego, J. A., Nachbar, J., Olshanskiy, V., Kishimoto, T., & Kane, J. M. (2011). Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research, 131(1–3), 58–62.CrossRefPubMedPubMedCentral

Covell, N. H., Jackson, C. T., Evans, A. C., & Essock, S. M. (2002). Antipsychotic prescribing practices in Connecticut’s public mental health system: Rates of changing medications and prescribing styles. Schizophrenia Bulletin, 28(1), 17–29.CrossRefPubMed

Crystal, S., Akincigil, A., Bilder, S., & Walkup, J. T. (2007). Studying prescription drug use and outcomes with medicaid claims data: Strengths, limitations, and strategies. Medical Care, 45(10 Supl 2), S58–S65.

Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998). Comorbidity measures for use with administrative data. Medical Care, 36(1), 8–27.CrossRefPubMed

Fleischhacker, W. W., & Uchida, H. (2014). Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 17(7), 1083–1093.CrossRef

Freudenreich, O., & Goff, D. C. (2002). Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scandinavica, 106(12366465), 323–330.CrossRefPubMed

Gallego, J. A., Bonetti, J., Zhang, J., Kane, J. M., & Correll, C. U. (2012). Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophrenia Research, 138(1), 18–28.CrossRefPubMedPubMedCentral

Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004). Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. The Journal of Clinical Psychiatry, 65(15491242), 1377–1388.CrossRefPubMed

Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., & Jeste, D. V. (2007). Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999–2004. Psychiatric Services, 58(7), 1007–1010.CrossRefPubMed

Goodwin, G., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., de Hert, M.,..., & Zohar, J. (2009). Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, nice. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 19(7), 520–532.CrossRef

Henderson, D. C., & Goff, D. C. (1996). Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. The Journal of Clinical Psychiatry, 57(9), 395–397.PubMed

Hennessy, S., Bilker, W. B., Weber, A., & Strom, B. L. (2003). Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiology and Drug Safety, 12(2), 103–111.CrossRefPubMed

Horvitz-Lennon, M., McGuire, T. G., Alegria, M., & Frank, R. G. (2009). Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. Health Services Research, 44(6), 2106–2122.CrossRefPubMedPubMedCentral

Horvitz-Lennon, M., Volya, R., Garfield, R., Donohue, J. M., Lave, J. R., & Normand, S. L. (2015). Where you live matters: quality and racial/ethnic disparities in schizophrenia care in four state medicaid programs. Health Services Research, 50(5), 1710–1729.CrossRefPubMedPubMedCentral

Howell, E. M. (1996). Medicaid managed care encounter data: what, why, and where next? Health Care Financing Review, 17(4), 87–95.PubMedPubMedCentral

Jeste, D. V., Caligiuri, M. P., Paulsen, J. S., Heaton, R. K., Lacro, J. P., Harris, M. J.,..., & McAdams, L. A. (1995). Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52(9), 756–765.CrossRefPubMed

Joukamaa, M., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry: The Journal of Mental Science, 188, 122–127.CrossRef

Kessing, L. V., Thomsen, A. F., Mogensen, U. B., & Andersen, P. K. (2010). Treatment with antipsychotics and the risk of diabetes in clinical practice. The British Journal of Psychiatry: The Journal of Mental Science, 197(4), 266–271.CrossRef

Kronick, R. G., & Gilmer, B. M. (2009). The faces of Medicaid III: refining the portrait of people with multiple chronic conditions. Hamilton, NJ: Center for Health Care Strategies.

Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., & Perkins, D. O. (2004). Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 161(2 Suppl), 1–56.PubMed

Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., & Kreyenbuhl, J. (2004). Practice guideline for the treatment of patients with schizophrenia. The American Journal of Psychiatry, 161(2 Suppl), 1–56.PubMed

Lemmens, P., Brecher, M., & Van Baelen, B. (1999). A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms. Acta Psychiatrica Scandinavica, 99(3), 160–170.CrossRefPubMed

Mallinger, J. B., Fisher, S. G., Brown, T., & Lamberti, J. S. (2006). Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatric Services, 57(1), 133–136.CrossRefPubMed

Manuel, J. I., Essock, S. M., Wu, Y., Pangilinan, M., & Stroup, S. (2012). Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatric Services, 63(11), 1146–1149.CrossRefPubMed

McIntyre, R. S., & Jerrell, J. M. (2008). Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives of Pediatrics and Adolescent Medicine, 162(10), 929–935.CrossRefPubMed

Megna, J. L., Kunwar, A. R., Mahlotra, K., Sauro, M. D., Devitt, P. J., & Rashid, A. (2007). A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. Journal of Psychiatric Practice, 13(2), 129–137.CrossRefPubMed

Miller, A., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R.,..., & Tarin-Godoy, B. (2004). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. The Journal of Clinical Psychiatry, 65(4), 500–508.CrossRefPubMed

Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67(1), 26–36.CrossRefPubMed

Moore, T. A., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L.,...., & Miller, A. L. (2007). The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. The Journal of Clinical Psychiatry, 68(11), 1751–1762.CrossRefPubMed

Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., & Valuck, R. J. (2007). Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: Experience in a multistate Medicaid population, 1998–2003. Clinical Therapeutics, 29(17379060), 183–195.CrossRefPubMed

Naber, D., Holzbach, R., Perro, C., & Hippius, H. (1992). Clinical management of clozapine patients in relation to efficacy and side-effects. The British Journal of Psychiatry. 17, 54–59.CrossRef

Nielsen, J., le Quach, P., Emborg, C., Foldager, L., & Correll, C. U. (2010). Ten-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatrica Scandinavica, 122(5), 356–366.CrossRefPubMed

Owen, R. R., Hudson, T., Thrush, C., Thapa, P., Armitage, T., & Landes, R. D. (2008). The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia. Medical Care, 46(7), 686–691.CrossRefPubMed

Sabin, J. E., & Daniels, N. (2003a). Improving psychiatric drug benefit management: II. Kaiser Permanente’s approach to SSRIs. Psychiatric Services, 54(10), 1343–1344.CrossRefPubMed

Sabin, J. E., & Daniels, N. (2003b). Managed care: Improving psychiatric drug benefit management: I. Lessons from Massachusetts. Psychiatric Services, 54(7), 949–951.CrossRefPubMed

Seabury, S. A., Goldman, D. P., Kalsekar, I., Sheehan, J. J., Laubmeier, K., & Lakdawalla, D. N. (2014). Formulary restrictions on atypical antipsychotics: Impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. The American Journal of Managed Care, 20(2), e52–e60.

Sneider, B., Pristed, S. G., Correll, C. U., & Nielsen, J. (2015). Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 25(10), 1669–1676.CrossRef

Stahl, S. M. (2002). Antipsychotic polypharmacy: Evidence based or eminence based? Acta Psychiatrica Scandinavica, 106(5), 321–322.CrossRefPubMed

Stahl, S. M., & Grady, M. M. (2004). A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry, 11(3), 313–327.CrossRefPubMed

Stahl, S. M., & Grady, M. M. (2006). High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatric Services, 57(1), 127–129.CrossRefPubMed

Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2014). Geographic and clinical variation in clozapine use in the United States. Psychiatric Services, 65(2), 186–192.CrossRefPubMed

Sun, F., Stock, E. M., Copeland, L. A., Zeber, J. E., Ahmedani, B. K., & Morissette, S. B. (2014). Polypharmacy with antipsychotic drugs in patients with schizophrenia: Trends in multiple health care systems. American Journal of Health-System Pharmacy: Ajhp: Official Journal of the American Society of Health-System Pharmacists, 71(9), 728–738.CrossRef

Suzuki, T., Watanabe, U. H., Mimura, K. M. (2013). Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice?. Polypharmacy in psychiatry practice (Vol II) Use of polypharmacy in the ‘real world’ (Vol. 2, pp. 81–107). Dordrecht: Springer

Sweeney, J. A., Keilp, J. G., Haas, G. L., Hill, J., & Weiden, P. J. (1991). Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Research, 37(3), 297–308.CrossRefPubMed

Tapp, A., Wood, A. E., Secrest, L., Erdmann, J., Cubberley, L., & Kilzieh, N. (2003). Combination antipsychotic therapy in clinical practice. Psychiatric Services, 54(1), 55–59.CrossRefPubMed

The Joint Commission. (2013). Specification manual for national quality measures—hospital-based inpatient psychiatric services. Retrieved June 17, 2016 from https://manual.jointcommission.org/releases/TJC2013A/HospitalBasedInpatientPsychiatricServices.html.

Thompson, A., Sullivan, S. A., Barley, M., Strange, S. O., Moore, L., Rogers, P.,..., & Harrison, G. (2008). The DEBIT trial: An intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards—a cluster randomized controlled trial. Psychological Medicine, 38(5), 705–715.CrossRefPubMed

Tirupati, S., & Chua, L. E. (2007). Obesity and metabolic syndrome in a psychiatric rehabilitation service. The Australian and New Zealand Journal of Psychiatry, 41(7), 606–610.CrossRefPubMed

US Department of Health and Human Services. (2005). Area health resources files. Rockville, MD: Health Resources and Services Administration, Bureau of Health Workforce.

Van Duin, D., Franx, G., Van Wijngaarden, B., Van Der Gaag, M., Van Weeghel, J., Slooff, C., & Wensing, M. (2013). Bridging the science-to-service gap in schizophrenia care in the Netherlands: The Schizophrenia quality improvement collaborative. International Journal for Quality in Health Care: Journal of the International Society for Quality in Health Care/ISQua, 25(6), 626–632.CrossRef

van Walraven, C., Austin, P. C., Jennings, A., Quan, H., & Forster, A. J. (2009). A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Medical Care, 47(6), 626–633.CrossRefPubMed

Velligan, D. I., Carroll, C., Lage, M. J., & Fairman, K. (2015). Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatric Services, 66(2), 127–133.CrossRefPubMed

Verier, J., & Zlatinov A. (2013). Trends and patterns in the use of prescription drugs among Medicaid beneficiaries: 1999 to 2009. Medicaid policy brief, 17. Retrieved March 30, 2003 from http://www.mathematica-mpr.com/~/media/publications/pdfs/health/max_ib17.pdf website.

Vinogradov, S., Fisher, M., Warm, H., Holland, C., Kirshner, M. A., & Pollock, B. G. (2009). The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. The American Journal of Psychiatry, 166(9), 1055–1062.CrossRefPubMedPubMedCentral

Vogt, W. B., Joyce, G., Xia, J., Dirani, R., Wan, G., & Goldman, D. P. (2011). Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics. Health Affairs, 30(12), 2346–2354.CrossRefPubMed

Waddington, J. L., Youssef, H. A., & Kinsella, A. (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. The British Journal of Psychiatry: The Journal of Mental Science, 173, 325–329.CrossRef

Wu, E. Q., Shi, L., Birnbaum, H., Hudson, T., & Kessler, R. (2006). Annual prevalence of diagnosed schizophrenia in the USA: A claims data analysis approach. Psychological Medicine, 36(11), 1535–1540.CrossRefPubMed

Zhu, B., Ascher-Svanum, H., Faries, D. E., Correll, C. U., & Kane, J. M. (2008). Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry, 8(18394168), 19–19.CrossRefPubMedPubMedCentral

Titel: Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy
verfasst von: Robert O. Cotes
David R. Goldsmith
Sarah L. Kopelovich
Cathy A. Lally
Benjamin G. Druss
Publikationsdatum: 10.11.2017
Verlag: Springer US
Erschienen in: Community Mental Health Journal / Ausgabe 6/2018
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-017-0183-y

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Lifetime Trauma and Depressive Symptomatology Among Older American Indians: The Native Elder Care Study

Reasons for Nonadherence to Psychiatric Medication and Cardiovascular Risk Factors Treatment Among Latino Bipolar Disorder Patients Living in Puerto Rico: A Qualitative Study

The Role of Public Health in the Development of a Collaborative Agreement with Rural and Semi-urban Partners in Cases of Severe Domestic Squalor and Hoarding

Public Awareness and Attitude Towards Depression: A Community Based Study Among an Adult Population in Ile-Ife South-Western Nigeria

Mental Health in China: Stigma, Family Obligations, and the Potential of Peer Support